Aratana Therapeutics Inc.

aratana.com

Aratana Therapeutics, Inc. (Nasdaq: PETX) is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for cats and dogs. Aratana is a fast-growing company headquartered in the greater Kansas City area focused on delivering safe and effective therapeutics that elevate the standard of care in veterinary medicine. As a pioneer in pet therapeutics, Aratana’s goal is to work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

news image

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More

Pharma Tech

IACTA PHARMACEUTICALS AND TALLC CORPORATION ANNOUNCE STRATEGIC COLLABORATION TO UTILIZE NOVEL SMARTCELLE TOPICAL DELIVERY TECHNOLOGY

IACTA Pharmaceuticals, Inc. | December 16, 2021

news image

IACTA Pharmaceuticals, Inc. an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, announced that they are entering into a strategic collaboration and licensing agreement. The agreement grants IACTA the use of TALLC’s proprietary SmartCelle™ micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development. IACTA...

Read More

Business Insights, PHARMA TECH

AVACTA COMPLETES FOURTH DOSE ESCALATION IN AVA6000 PHASE 1 CLINICAL STUDY

Avacta | January 23, 2023

news image

Avacta Group plc, a leading life sciences company focused on developing innovative, targeted oncology medicines and powerful diagnostics, recently announced that AVA6000 has maintained a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Furthermore, analysis of tumor samples acquired from six patients across multiple cohorts shows that doxorubicin is being released within the tumor tissue, supporting the pre|CISIONTM technol...

Read More

Pharma Tech

AQUAVIT FURTHER PREVAILS AGAINST COUNTERFEITERS IN U S FOLLOWING ITS RECENT VICTORY IN EUROPE

Aquavit Pharmaceuticals, Inc | March 22, 2022

news image

Aquavit Pharmaceuticals, Inc continues to succeed in its intellectual property cases against counterfeiters both domestically and abroad. Following a recent win against counterfeiter U-BioMed, Inc. across the European Union, the U.S. Southern District Court of New York adopted Judge Lehrburger's recommendations that any sanctions related to U-BioMed's deletion of its Instagram account, which blatantly exploited Aquavit's AQUAGOLD product illegally, be folded into the p...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More
news image

Pharma Tech

IACTA PHARMACEUTICALS AND TALLC CORPORATION ANNOUNCE STRATEGIC COLLABORATION TO UTILIZE NOVEL SMARTCELLE TOPICAL DELIVERY TECHNOLOGY

IACTA Pharmaceuticals, Inc. | December 16, 2021

IACTA Pharmaceuticals, Inc. an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, announced that they are entering into a strategic collaboration and licensing agreement. The agreement grants IACTA the use of TALLC’s proprietary SmartCelle™ micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development. IACTA...

Read More
news image

Business Insights, PHARMA TECH

AVACTA COMPLETES FOURTH DOSE ESCALATION IN AVA6000 PHASE 1 CLINICAL STUDY

Avacta | January 23, 2023

Avacta Group plc, a leading life sciences company focused on developing innovative, targeted oncology medicines and powerful diagnostics, recently announced that AVA6000 has maintained a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Furthermore, analysis of tumor samples acquired from six patients across multiple cohorts shows that doxorubicin is being released within the tumor tissue, supporting the pre|CISIONTM technol...

Read More
news image

Pharma Tech

AQUAVIT FURTHER PREVAILS AGAINST COUNTERFEITERS IN U S FOLLOWING ITS RECENT VICTORY IN EUROPE

Aquavit Pharmaceuticals, Inc | March 22, 2022

Aquavit Pharmaceuticals, Inc continues to succeed in its intellectual property cases against counterfeiters both domestically and abroad. Following a recent win against counterfeiter U-BioMed, Inc. across the European Union, the U.S. Southern District Court of New York adopted Judge Lehrburger's recommendations that any sanctions related to U-BioMed's deletion of its Instagram account, which blatantly exploited Aquavit's AQUAGOLD product illegally, be folded into the p...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us